Viatris is a healthcare company. Co.'s portfolio comprises of approved molecules across a range of therapeutic areas, including brands, generic, complex generic and biosimilars. From cardiovascular health to oncology, Co. provides treatment options across therapeutic areas covering a variety of non-communicable and infectious diseases. Co. also provides support services such as diagnostic clinics, educational seminars and digital tools. Co. provides a range of treatment options across all its therapeutic areas, with several categories containing several products in a range of dosage forms, formulations and delivery systems that allow physicians to tailor care for optimal treatment. The VTRS stock yearly return is shown above.
The yearly return on the VTRS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VTRS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|